beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells.
We have investigated the in vitro effects of the neurohormone beta-endorphin (b-end) on natural killer (NK) activity and interferon (IFN) production mediated by large granular lymphocytes (LGL). LGL-enriched fractions from peripheral blood mononuclear cells (PBMC) from normal human volunteers were obtained by fractionation over discontinuous Percoll gradients. LGL were preincubated with or without various concentrations of b-end or the closely related peptides alpha-endorphin (a-end), gamma-endorphin (g-end), or D-ALA2-beta-endorphin (D-ALA2-b-end), a synthetic b-end analogue. NK activity was assayed on 51Cr-labeled K562 target cells. Preincubation of LGL effectors (but not K562 targets) for 2 to 18 hr with concentrations of b-end between 10(-7) M and 10(-10) M produced significant augmentation of NK cytolytic activity (mean percentage increase: 63%). The classic opiate antagonist naloxone blocked the enhancing effect when used at a 100-fold molar excess relative to b-end. Neither a-end nor g-end could augment NK activity, whereas D-ALA2-b-end produced an enhancement comparable with that produced by b-end. In addition, incubation of LGL with b-end in the presence of phytohemagglutinin or poly I:C significantly augmented IFN production. These findings demonstrate that b-end enhances NK activity and IFN production of purified LGL, and suggests that b-end might bind to an opioid receptor on LGL that can be blocked by naloxone. These results lend support to the concepts of regulation of the immune response by neurohormones and the functional relationship between the nervous and immune systems.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000906:Antibodies / Q000502:physiology; D002469:Cell Separation; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004306:Dose-Response Relationship, Immunologic; D004723:Endorphins / Q000494:pharmacology*; D006801:Humans; D007369:Interferon Inducers / Q000494:pharmacology*; D007370:Interferon Type I / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000145:classification; D001615:beta-Endorphin
D000276:Adjuvants, Immunologic; D000906:Antibodies; D004723:Endorphins; D007369:Interferon Inducers; D007370:Interferon Type I; D001615:beta-Endorphin; D007371:Interferon-gamma